BofA analyst Jason Gerberry raised the firm’s price target on Amylyx (AMLX) to $19 from $15 and keeps a Buy rating on the shares. The firm’s raised target reflects its updated view on lead drug, avexitide, in post-bariatric hypoglycemia, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx price target raised to $19 from $18 at Mizuho
- Amylyx price target raised to $28 from $20 at H.C. Wainwright
- Buy Rating on Amylyx: Avexitide’s High Unmet Need, Strong PBH Opportunity, and Clear Phase III Catalyst Support Upside
- Amylyx Advances AMX0318 as New Rare-Disease Candidate
- Amylyx selects AMX0318 as development candidate for PBH